Research Paper Volume 3, Issue 12 pp 1169—1177
Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass
Figure 4. Chronic Oxt infusion promotes use of fat and improves glucose tolerance. (A, B) Effect of chronic Oxt infusion on the time course of respiratory quotient (RQ) (A) and average RQ in the light and dark phases (B). Each value in panel A represents the average of 6 measurement points during 0.5 hr. (C, D) Effect of chronic Oxt infusion on the time course of energy expenditure (EE) (C) and its average values for the light and dark phases (D). Each value in C represents the average of 6 points measured in 0.5 hr (C). (E, F) Effect of chronic Oxt infusion on the time course of cumulative locomotor activity every 0.5 hr (E) and its average values in the light and dark phases (F). (G, H) Blood glucose levels during ip GTT (2 g/kg glucose injection, n = 18 for Oxt and 16 for control) at day 7 (G), and those during ITT (1 IU/kg human insulin injection, n = 18 for Oxt and 16 for control) at day 11 (H). (I) Systolic blood pressure for 5 days from day 8 to 12 after beginning of Oxt infusion. n = 5 in each group. *p < 0.05, **p < 0.01.